Aptamer Group (LSE:APTA) EBITDA Margin %: -132.73% (As of Dec. 2025)


What is Aptamer Group EBITDA Margin %?

Aptamer Group LSE:APTA EBITDA Margin % is -132.73% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Aptamer Group ranks worse than 59.15% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aptamer Group's EBITDA for the six months ended in Dec. 2025 was £-1.10 Mil. Aptamer Group's Revenue for the six months ended in Dec. 2025 was £0.83 Mil. Therefore, Aptamer Group's EBITDA margin for the quarter that ended in Dec. 2025 was -132.73%.

Aptamer Group  (LSE:APTA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Aptamer Group EBITDA Margin % Related Terms

Aptamer Group EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Aptamer Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptamer Group EBITDA Margin % Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial -85.85 -52.95 -271.97 -327.44 -189.86

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -586.91 -189.86 -161.41 -223.64 -132.73

LSE:APTA vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Aptamer Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptamer Group EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptamer Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aptamer Group's EBITDA Margin % falls into.


Aptamer Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aptamer Group's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-2.284/1.203
=-189.86 %

Aptamer Group's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.099/0.828
=-132.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -132.73% mean?
Aptamer Group (LSE:APTA) has a EBITDA Margin % of -132.73% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aptamer Group and its competitors. According to the industry distribution chart, Aptamer Group ranks #559 out of 945 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Aptamer Group's EBITDA Margin % too high?
Aptamer Group's current EBITDA Margin % is -132.73%. Based on the distribution chart, Aptamer Group ranks #559 out of 945 companies in the Biotechnology industry, which is below the industry midpoint.
How does Aptamer Group's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptamer Group ranks #559 out of 945 companies for EBITDA Margin %. This places Aptamer Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aptamer Group and its competitors. Aptamer Group's current EBITDA Margin % is -132.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptamer Group stock overvalued right now?
Aptamer Group (LSE:APTA) has a current EBITDA Margin % of -132.73%. The current EBITDA Margin % is -132.73%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aptamer Group (LSE:APTA), the current EBITDA Margin % is -132.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptamer Group Business Description

Other Exchanges P0J:Germany
Address Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses, Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics. The Group represents a single operating segment being research and experimental development of biotechnology. It operates in United Kingdom, Europe, USA and others.